SITE Centers logo

SITE CentersNYSE: SITC

Profile

Industry:

Retail

Country:

United States

IPO:

02 February 1993

Next earnings report:

13 February 2025

Last dividends:

18 June 2024

Next dividends:

N/A
$818.96 M
-74%vs. 3y high
40%vs. sector
-94%vs. 3y high
0%vs. sector
-78%vs. 3y high
11%vs. sector
-74%vs. 3y high
26%vs. sector

Price

after hours | Fri, 15 Nov 2024 23:45:18 GMT
$15.62+$0.12(+0.77%)
$90.76 M$73.09 M
$90.76 M$322.95 M

Analysts recommendations

Institutional Ownership

SITC Latest News

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
globenewswire.com11 November 2024 Sentiment: POSITIVE

Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
globenewswire.com08 November 2024 Sentiment: POSITIVE

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
prnewswire.com08 November 2024 Sentiment: POSITIVE

Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025 SAN JOSE, Calif. , Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas.

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
globenewswire.com08 November 2024 Sentiment: POSITIVE

BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX.

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
businesswire.com08 November 2024 Sentiment: POSITIVE

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024. “We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-spe.

Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
prnewswire.com07 November 2024 Sentiment: POSITIVE

HONG KONG , Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47.

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
globenewswire.com07 November 2024 Sentiment: POSITIVE

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation

Strong Evidence of AU-007's Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
businesswire.com07 November 2024 Sentiment: POSITIVE

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 dose escalation and cohort expansion study of AU-007. The data will be presented in a poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston, Texas. Preliminary Phase 2 data reveal that a combination of AU-007 and low-dose,.

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
globenewswire.com07 November 2024 Sentiment: POSITIVE

- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
globenewswire.com07 November 2024 Sentiment: POSITIVE

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -

What type of business is SITE Centers?

SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.

What sector is SITE Centers in?

SITE Centers is in the Real Estate sector

What industry is SITE Centers in?

SITE Centers is in the Retail industry

What country is SITE Centers from?

SITE Centers is headquartered in United States

When did SITE Centers go public?

SITE Centers initial public offering (IPO) was on 02 February 1993

What is SITE Centers website?

https://www.sitecenters.com

Is SITE Centers in the S&P 500?

No, SITE Centers is not included in the S&P 500 index

Is SITE Centers in the NASDAQ 100?

No, SITE Centers is not included in the NASDAQ 100 index

Is SITE Centers in the Dow Jones?

No, SITE Centers is not included in the Dow Jones index

When was SITE Centers the previous earnings report?

No data

When does SITE Centers earnings report?

The next expected earnings date for SITE Centers is 13 February 2025